keyword
MENU ▼
Read by QxMD icon Read
search

radioembolisation

keyword
https://www.readbyqxmd.com/read/29740687/radioembolisation-in-europe-a-survey-amongst-cirse-members
#1
Margot T M Reinders, Etienne Mees, Maciej J Powerski, Rutger C G Bruijnen, Maurice A A J van den Bosch, Marnix G E H Lam, Maarten L J Smits
INTRODUCTION: Radioembolisation of liver tumours demands many choices from the physician regarding planning of treatment and subsequent follow-up. METHODS: An online questionnaire was distributed amongst all members of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) to investigate the current state of radioembolisation practice. RESULTS: The survey was completed by 60 centres. The increasing number of radioembolisation procedures may reflect that radioembolisation is increasingly recognised as a valuable treatment option in European cancer guidelines...
May 8, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29516130/radioembolisation-in-patients-with-hepatocellular-carcinoma-that-have-previously-received-liver-directed-therapies
#2
Bruno Sangro, Carlo Ludovico Maini, Giuseppe Maria Ettorre, Roberto Cianni, Rita Golfieri, Daniele Gasparini, Samer Ezziddin, Philipp M Paprottka, Francesco Fiore, Mark Van Buskirk, Jose Ignacio Bilbao, Rita Salvatori, Emanuela Giampalma, Onelio Geatti, Kai Wilhelm, Ralf Thorsten Hoffmann, Francesco Izzo, Mercedes Iñarrairaegui, Carlo Urigo, Alberta Cappelli, Alessandro Vit, Hojjat Ahmadzadehfar, Tobias Franz Jakobs, Rosa Sciuto, Giuseppe Pizzi, Secondo Lastoria
PURPOSE: Radioembolisation is part of the multimodal treatment of hepatocellular carcinoma (HCC) at specialist liver centres. This study analysed the impact of prior treatment on tolerability and survival following radioembolisation. METHODS: This was a retrospective analysis of 325 consecutive patients with a confirmed diagnosis of HCC, who received radioembolisation with yttrium-90 resin microspheres at eight European centres between September 2003 and December 2009...
March 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29440463/immune-activation-underlies-a-sustained-clinical-response-to-yttrium-90-radioembolisation-in-hepatocellular-carcinoma
#3
Valerie Chew, Yun Hua Lee, Lu Pan, Nurul J M Nasir, Chun Jye Lim, Camillus Chua, Liyun Lai, Sharifah Nur Hazirah, Tony Kiat Hon Lim, Brian K P Goh, Alexander Chung, Richard H G Lo, David Ng, Rene L F Filarca, Salvatore Albani, Pierce K H Chow
OBJECTIVES: Yttrium-90 (Y90)-radioembolisation (RE) significantly regresses locally advanced hepatocellular carcinoma and delays disease progression. The current study is designed to deeply interrogate the immunological impact of Y90-RE, which elicits a sustained therapeutic response. DESIGN: Time-of-flight mass cytometry and next-generation sequencing (NGS) were used to analyse the immune landscapes of tumour-infiltrating leucocytes (TILs), tumour tissues and peripheral blood mononuclear cells (PBMCs) at different time points before and after Y90-RE...
February 13, 2018: Gut
https://www.readbyqxmd.com/read/29032802/radioembolisation-of-hepatocellular-carcinoma-a-primer
#4
REVIEW
N Venkatanarasimha, A Gogna, K T A Tong, K Damodharan, P K H Chow, R H G Lo, S Chandramohan
Transarterial radioembolisation (TARE) has gained increasing acceptance as an additional/alternative locoregional treatment option for hepatocellular carcinoma, and colorectal hepatic metastases that present beyond potentially curative options. This is a catheter-based transarterial selective internal brachytherapy that involves injection of radioactive microspheres (usually Y-90) that are delivered selectively to the liver tumours. Owing to the combined radioactive and microembolic effect, the findings at follow-up imaging are significantly different from that seen with other transarterial treatment options...
December 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28837044/estimation-of-lung-shunt-fraction-from-simultaneous-fluoroscopic-and-nuclear-images
#5
Sandra van der Velden, Remco Bastiaannet, Arthur J A T Braat, Marnix G E H Lam, Max A Viergever, Hugo W A M de Jong
Radioembolisation with yttrium-90 (90Y) is increasingly used as a treatment of unresectable liver malignancies. For safety, a scout dose of technetium-99m macroaggregated albumin (99mTc-MAA) is used prior to the delivery of the therapeutic activity to mimic the deposition of 90Y. One-day procedures are currently limited by the lack of nuclear images in the intervention room. To cope with this limitation, an interventional simultaneous fluoroscopic and nuclear imaging device is currently being developed. The purpose of this simulation study was to evaluate the accuracy of estimating the lung shunt fraction (LSF) of the scout dose in the intervention room with this device and compare it against current clinical methods...
October 12, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28758319/treatment-options-for-unresectable-hcc-with-a-focus-on-sirt-with-yttrium-90-resin-microspheres
#6
REVIEW
Eric A Wang, Jeff P Stein, Ross J Bellavia, Scott R Broadwell
Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the second leading cause of cancer-related deaths across the globe. Only a small percentage of HCC patients (~20%-30%) are diagnosed at an early stage when first-line treatment options may be effective. The majority of HCC patients (>70%) are diagnosed with unresectable disease and given a poor overall prognosis. Current treatment guidelines recommend locoregional therapy with transarterial chemoembolisation (TACE) and systemic therapy with sorafenib as first-line treatment for patients with intermediate and advanced stage HCC...
July 30, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28710583/prototype-metal-artefact-reduction-algorithm-in-flat-panel-computed-tomography-evaluation-in-patients-undergoing-transarterial-hepatic-radioembolisation
#7
Qeumars Mustafa Hamie, Adrian Raoul Kobe, Leif Mietzsch, Michael Manhart, Gilbert Dominique Puippe, Thomas Pfammatter, Roman Guggenberger
OBJECTIVE: To investigate the effect of an on-site prototype metal artefact reduction (MAR) algorithm in cone-beam CT-catheter-arteriography (CBCT-CA) in patients undergoing transarterial radioembolisation (RE) of hepatic masses. METHODS AND MATERIALS: Ethical board approved retrospective study of 29 patients (mean 63.7±13.7 years, 11 female), including 16 patients with arterial metallic coils, undergoing CBCT-CA (8s scan, 200 degrees rotation, 397 projections)...
January 2018: European Radiology
https://www.readbyqxmd.com/read/28685382/safety-and-efficacy-of-transarterial-radioembolisation-in-patients-with-intermediate-or-advanced-stage-hepatocellular-carcinoma-refractory-to-chemoembolisation
#8
Elisabeth G Klompenhouwer, Raphaëla C Dresen, Chris Verslype, Annouschka Laenen, Gert De Hertogh, Christophe M Deroose, Lawrence Bonne, Vincent Vandevaveye, Geert Maleux
INTRODUCTION: Transarterial chemoembolisation (TACE) is the most widely used locoregional treatment for patients with an unresectable hepatocellular carcinoma (HCC). Transarterial radioembolisation (TARE) with yttrium-90 containing microspheres is an emerging interventional treatment that could be complementary or an alternative to TACE. AIM: To evaluate the safety and efficacy of TARE in patients with HCC who are refractory to TACE with drug-eluting beads (DEB-TACE)...
July 6, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28677067/intra-arterial-therapy-of-neuroendocrine-tumour-liver-metastases-comparing-conventional-tace-drug-eluting-beads-tace-and-yttrium-90-radioembolisation-as-treatment-options-using-a-propensity-score-analysis-model
#9
Duc Do Minh, Julius Chapiro, Boris Gorodetski, Qiang Huang, Cuihong Liu, Susanne Smolka, Lynn Jeanette Savic, David Wainstejn, MingDe Lin, Todd Schlachter, Bernhard Gebauer, Jean-François Geschwind
OBJECTIVES: To compare efficacy, survival outcome and prognostic factors of conventional transarterial chemoembolisation (cTACE), drug-eluting beads TACE (DEB-TACE) and yttrium-90 radioembolisation (Y90) for the treatment of liver metastases from gastroenteropancreatic (GEP) neuroendocrine tumours (NELM). METHODS: This retrospective analysis included 192 patients (58.6 years mean age, 56% men) with NELM treated with cTACE (N = 122), DEB-TACE (N = 26) or Y90 (N = 44) between 2000 and 2014...
December 2017: European Radiology
https://www.readbyqxmd.com/read/28674968/recommendations-for-radioembolisation-after-liver-surgery-using-yttrium-90-resin-microspheres-based-on-a-survey-of-an-international-expert-panel
#10
Morsal Samim, Linde M van Veenendaal, Manon N G J A Braat, Andor F van den Hoven, Richard Van Hillegersberg, Bruno Sangro, Yung Hsiang Kao, Dave Liu, John D Louie, Daniel Y Sze, Steven C Rose, Daniel B Brown, Hojjat Ahmadzadehfar, Edward Kim, Maurice A A J van den Bosch, Marnix G E H Lam
INTRODUCTION: Guidelines on how to adjust activity in patients with a history of liver surgery who are undergoing yttrium-90 radioembolisation (90Y-RE) are lacking. The aim was to study the variability in activity prescription in these patients, between centres with extensive experience using resin microspheres 90Y-RE, and to draw recommendations on activity prescription based on an expert consensus. METHODS: The variability in activity prescription between centres was investigated by a survey of international experts in the field of 90Y-RE...
December 2017: European Radiology
https://www.readbyqxmd.com/read/28656502/update-on-treatment-options-for-advanced-bile-duct-tumours-radioembolisation-for-advanced-cholangiocarcinoma
#11
REVIEW
Pavan Najran, Angela Lamarca, Damian Mullan, Mairéad G McNamara, Thomas Westwood, Richard A Hubner, Jeremy Lawrence, Prakash Manoharan, Jon Bell, Juan W Valle
Cholangiocarcinoma is a rare form of gastrointestinal cancer with a poor prognosis. Patients often present with biliary obstruction or non-specific abdominal pain, and a high proportion of patients have advanced disease at initial diagnosis. The goal of this review is to discuss treatment options for patients with advanced bile duct tumours focusing on radioembolisation (RE) and its impact on overall survival. RE provides a therapeutic option for patients with unresectable cholangiocarcinoma. However, although systemic chemotherapy has demonstrated a survival benefit in randomised controlled trials, there is limited supporting evidence for the use of RE in this setting...
July 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28634669/yttrium-90-y-90-resin-microsphere-therapy-for-patients-with-unresectable-hepatocellular-carcinoma-a-single-center-experience
#12
Semra İnce, Bülent Karaman, Engin Alagoz, Nuri Karadurmuş, Hüseyin Şan, Cemal Nuri Erçin, Nuri Arslan
BACKGROUND/AIM: Selective intraarterial radionuclide therapy (SIRT) with yttrium-90 (Y-90) resin microspheres presently has successful results in primary or metastatic inoperable liver tumors. This procedure, which is also known as radioembolisation, delivers high doses of radiation selectively to hepatic tumors while minimum healthy liver exposure. The aim of this study was to present our clinical experience of radiomicrosphere therapy for the treatment of patients with unresectable hepatocellular carcinoma (HCC)...
June 20, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28536968/clinical-and-imaging-based-prognostic-factors-in-radioembolisation-of-liver-metastases-from-colorectal-cancer-a-retrospective-exploratory-analysis
#13
Kathy P Willowson, Aimee R Hayes, David L H Chan, Michael Tapner, Elizabeth J Bernard, Richard Maher, Nick Pavlakis, Stephen J Clarke, Dale L Bailey
BACKGROUND: The aim of this study was to investigate the relationship between absorbed dose and response of colorectal cancer liver metastases treated with [(90)Y]-resin microspheres and to explore possible clinical and imaging derived prognostic factors. METHODS: FDG PET/CT was used to measure response of individual lesions to a measured absorbed dose, derived from post-treatment (90)Y PET imaging. Predicted dose was also derived from planning [(99m)Tc]-MAA SPECT data...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28407278/prevention-and-treatment-of-complications-of-selective-internal-radiation-therapy-expert-guidance-and-systematic-review
#14
REVIEW
Bruno Sangro, Diego Martínez-Urbistondo, Lourens Bester, Jose I Bilbao, Douglas M Coldwell, Patrick Flamen, Andrew Kennedy, Jens Ricke, Ricky A Sharma
Selective internal radiation therapy (or radioembolization) by intra-arterial injection of radioactive yttrium-90-loaded microspheres is increasingly used for the treatment of patients with liver metastases or primary liver cancer. The high-dose beta-radiation penetrates an average of only 2.5 mm from the source, thus limiting its effects to the site of delivery. However, the off-target diversion of yttrium-90 microspheres to tissues other than the tumor may lead to complications. The most prominent of these complications include radiation gastritis and gastrointestinal ulcers, cholecystitis, radiation pneumonitis, and radioembolization-induced liver disease, which may occur despite careful pretreatment planning...
September 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28202430/vespro-an-individual-patient-data-prospective-meta-analysis-of-selective-internal-radiation-therapy-versus-sorafenib-for-advanced-locally-advanced-or-recurrent-hepatocellular-carcinoma-of-the-sarah-and-sirvenib-trials
#15
Val Gebski, Emma Gibbs, Mihir Gandhi, Gilles Chatellier, Aurelia Dinut, Helena Pereira, Pierce Kh Chow, Valérie Vilgrain
BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) has an overall poor prognosis. Currently there are 2 ongoing prospective randomized controlled trials that are evaluating the efficacy and safety of sorafenib and selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres in patients with advanced HCC. The SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma (SARAH; 459 patients) trial is being performed in Europe and the SIRt VErsus SorafeNIB (SIRveNIB; 360 patients) trial in the Asia Pacific region...
February 15, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/27993095/personnel-dose-reduction-in-90-y-microspheres-liver-directed-radioembolization-from-interventional-radiology-suite-to-patient-ward
#16
Martin Law, K K Wong, W K Tso, Victor Lee, M Y Luk, C C Tong, Ferdinand Chu
OBJECTIVE: To describe a method to reduce the external radiation exposure emitted from the patient after liver-directed radioembolization using 90 Y glass microspheres, to quantitatively estimate the occupational dose of medical personnel providing patient care to the patient radioembolized with the use of the method and to discuss radiation exposure to patients who are adjacent if the patient radioembolized needs hospitalization. METHODS: A lead-lined blanket of lead equivalence of 0...
March 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/27622200/treatment-response-after-radioembolisation-in-patients-with-hepatocellular-carcinoma-an-evaluation-with-dual-energy-computed-tomography
#17
Jens Altenbernd, Axel Wetter, Michael Forsting, Lale Umutlu
PURPOSE: The aim of this prospective study was to examine the diagnostic value of dual-energy CT (DECT) in the assessment of response of HCC after radioembolisation (RE). MATERIAL AND METHODS: 40 HCC patients with 82 measurable target lesions were included in this study. At baseline and follow-up examination target lesions were evaluated with (IU), AASLD and Choi measurement criteria. Disease control was defined as the sum of complete response (CR), partial response (PR), progression disease (PD) and stable disease (SD)...
2016: European Journal of Radiology Open
https://www.readbyqxmd.com/read/27307346/partition-model-based-99mtc-maa-spect-ct-predictive-dosimetry-compared-with-90y-tof-pet-ct-posttreatment-dosimetry-in-radioembolization-of-hepatocellular-carcinoma-a-quantitative-agreement-comparison
#18
COMPARATIVE STUDY
Silvano Gnesin, Laurent Canetti, Salim Adib, Nicolas Cherbuin, Marina Silva Monteiro, Pierre Bize, Alban Denys, John O Prior, Sebastien Baechler, Ariane Boubaker
(90)Y-microsphere selective internal radiation therapy (SIRT) is a valuable treatment in unresectable hepatocellular carcinoma (HCC). Partition-model predictive dosimetry relies on differential tumor-to-nontumor perfusion evaluated on pretreatment (99m)Tc-macroaggregated albumin (MAA) SPECT/CT. The aim of this study was to evaluate agreement between the predictive dosimetry of (99m)Tc-MAA SPECT/CT and posttreatment dosimetry based on (90)Y time-of-flight (TOF) PET/CT. METHODS: We compared the (99m)Tc-MAA SPECT/CT results for 27 treatment sessions (25 HCC patients, 41 tumors) with (90)Y SIRT (7 glass spheres, 20 resin spheres) and the posttreatment (90)Y TOF PET/CT results...
November 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27108297/liver-ct-for-vascular-mapping-during-radioembolisation-workup-comparison-of-an-early-and-late-arterial-phase-protocol
#19
COMPARATIVE STUDY
Andor F van den Hoven, Manon N G J A Braat, Jip F Prince, Pieter J van Doormaal, Maarten S van Leeuwen, Marnix G E H Lam, Maurice A A J van den Bosch
OBJECTIVES: To compare right gastric (RGA) and segment 4 artery (A4) origin detection rates during radioembolisation workup between early and late arterial phase liver CT protocols. METHODS: 100 consecutive patients who underwent liver CT between May 2012-January 2015 with early or late arterial phase protocol (n = 50 each, 10- vs. 20-s post-threshold delay) were included. RGA/A4 origin detection rates, assessed by two raters, and contrast-to-noise ratio (CNR) of the hepatic artery relative to the portal vein were compared between the protocols...
January 2017: European Radiology
https://www.readbyqxmd.com/read/27020341/origin-dosimetric-effect-and-clinical-limitations-of-the-semi-empirical-body-surface-area-method-for-radioembolisation-using-yttrium-90-resin-microspheres
#20
Yung Hsiang Kao, Meir Lichtenstein
No abstract text is available yet for this article.
June 2016: Journal of Medical Imaging and Radiation Oncology
keyword
keyword
73282
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"